PLAN for an Effective COVID-19 Response
Preparing Localities for Action Against Novel Coronavirus (PLAN) is a scenario-planning tool that identifies potential US supply and demand imbalances down to the county level.
Передовые технологии и развитие глобального рынка изменили медицинские технологии к лучшему, но лидерам отрасли предстоит в ближайшие годы взять на вооружение инновационные бизнес-модели, которые обеспечат компаниям рост. Ознакомьтесь с последними передовыми идеями BCG о медицинской технике и технологиях, чтобы узнать о ключевых факторах, влияющих на развитие медицинских технологий во всем мире.
Preparing Localities for Action Against Novel Coronavirus (PLAN) is a scenario-planning tool that identifies potential US supply and demand imbalances down to the county level.
Understanding how each new test works, what it can and cannot do, and when and under what circumstances it should be used is critical to avoiding confusion and misapplication.
We need better testing to get people treated and then get companies back to work.
In their response to COVID-19, pharma and medtech companies have been true to their purpose. They now face questions that go beyond addressing the virus itself.
A recent analysis shows disturbing variations in the use of a key diagnostic for lung cancer patients. Adopting new protocols and tools can lead to better care.
The revolution has come to health care. Artificial intelligence has major repercussions for players across the industry—as well as for new-technology entrants and consumers.
Commercial applications are poised to go mainstream. Pharma and medtech companies, payers, and providers need to engage with the technology now.
AI is gaining steam in business. Its rapid rise in China, in particular, has been a wake-up call for nations, industries, and executives globally.
Extracting value from service-based businesses requires a different approach than the traditional focus on product sales.
Companies can use their clinical knowledge, digital platforms, and access to data to develop profitable portfolios of value-added services.
Medtech companies have begun a long-overdue shift to disciplined, value-based pricing—the kind of pricing that can improve performance and fuel innovation.
BCG’s second global benchmarking study finds that the industry has made limited progress in fixing its commercial model. Yet firms that take action are posting strong shareholder returns.
A much more rigorous approach to value creation lets investor-held medtech firms win in the face of price erosion and other challenges.
In the past, high medtech manufacturing margins made inefficient production tolerable. Today, companies must rethink their manufacturing strategy—with big rewards for getting it right.
Hospitals are increasingly buying medtech products and services less on the basis of initial purchase price and more on the total value they create—for patients, clinical staff, and society.
Some medtech CEOs have embraced value-based health care and the business opportunity it represents, but many remain cautious. That’s understandable—but strategically misguided. Companies don’t have the luxury to wait.
Although women make up the majority of health care employees, men still dominate the corner office. Here are six ways to give women a fair shot at the top.
